Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma

Figure 4

(a) Flow cytometry, side scatter versus CD45, demonstrates a large, atypical lymphocyte population shifted into the blast/myeloid gate. (b) CD19 versus CD20 evaluation identifies a CD19/CD20 positive B lymphocyte population. (c) Surface kappa light chain restriction is indicative of monoclonal B lymphocyte population. (d) The neoplastic B cells are positive for CD19 and CD5. The previous plasmablastic neoplasm identified in this patient was CD20 and CD5 negative.

(a)

(b)

(c)

(d)